Procoagulant Phosphatidylserine-Exposing Platelets in vitro and in vivo

Emily C. Reddy and Margaret L. Rand

The physiological heterogeneity of platelets leads to diverse responses and the formation of discrete subpopulations upon platelet stimulation. Procoagulant platelets are an example of such subpopulations, a key characteristic of which is exposure either of the anionic aminophospholipid phosphatidylserine (PS) or of tissue factor on the activated platelet surface. This review focuses on the former, in which PS exposure on a subpopulation of platelets facilitates assembly of the intrinsic tenase and prothrombinase complexes, thereby accelerating thrombin generation on the activated platelet surface, contributing importantly to the hemostatic process. Mechanisms involved in platelet PS exposure, and accompanying events, induced by physiologically relevant agonists are considered then contrasted with PS exposure resulting from intrinsic pathway-mediated apoptosis in platelets. Pathologies of PS exposure, both inherited and acquired, are described. A consideration of platelet PS exposure as an antithrombotic target concludes the review.

Keywords: platelets, procoagulant, phosphatidylserine (PS) exposure, platelet activation, platelet apoptosis, hemostasis, thrombosis

INTRODUCTION

Blood vessel wall injury sets into play processes that lead to the formation of a hemostatic plug that stops the bleeding from the injury site. In primary hemostasis, platelets adhere to exposed subendothelium, resulting in their activation and aggregation, forming a platelet plug. Secondary hemostasis is initiated by tissue factor exposure at the site of vessel wall damage, resulting in formation, via the coagulation pathway, of covalently cross-linked fibrin that binds to, and stabilizes, the platelet plug (1). It has long been recognized that activated platelets contribute in a major way to fibrin formation; this is well-exemplified in the cell-based model of coagulation (2). This procoagulant property of platelets, earlier termed platelet factor 3 availability (PF3a) and assayed by measuring the ability of platelets to promote thrombin and fibrin formation (3), results from exposure of the anionic aminophospholipid phosphatidylserine (PS) on the surface of activated platelets (4). PS, translocated from the internal to the external platelet membrane leaflet, facilitates the assembly of the intrinsic tenase complex [factor (F)VIIIa; FIXa; FX] and prothrombinase complex (FVa; FXa; prothrombin), contributing to the burst of thrombin generation in the propagation phase of coagulation. Specifically, the negatively charged γ-carboxyglutamate (Gla) residues at the NH2 termini of the vitamin K-dependent factors, FIX(a), FX(a), and prothrombin, interact with negatively charged PS via Ca2+. FVIII binds to PS via its C2 domain and FVa via its C1 and C2
domains (5, 6). Tenase and prothrombinase activities are enhanced by PS-containing membranes by up to three orders of magnitude (7–9). Phosphatidylethanolamine (PE), that also becomes exposed on the surface of activated platelets, can contribute to the enhanced thrombin formation (7, 10); the fatty acid chain length of PE, but not PS, regulates the ability to support coagulation, with platelet-specific PEs demonstrating optimum activity (11). Oxidized PE, specifically 12-hydroxyecosatetraenoic acid (HETE)-PE, formed by activated platelets, is even more potent than native PE in enhancing thrombin generation (12).

It is recognized that tissue factor–expressing platelets also comprise a subpopulation of procoagulant platelets. However, a discussion of this type of procoagulant platelet is beyond the scope of this mini-review, and the reader is referred to several recent, relevant publications on the topic (13–18).

**Procoagulant Phosphatidylserine-Exposing Platelet Subpopulations and Nomenclature**

A unique feature of procoagulant platelet formation is that only a subpopulation of activated platelets exposes PS. This was recognized over 25 years ago by flow cytometry (19) using fluorescently labeled annexin A5 that binds PS with high affinity in a Ca²⁺-dependent manner. Fluorescently labeled lactadherin that does not require Ca²⁺ is also used to detect PS-exposing platelets [e.g., Dasgupta et al. (20)]. Flow cytometric and microscopy studies have shown colocalization of FVIII(a), FIX(a), FX(a), FV(a), and prothrombin with PS-exposing platelets, confirming that these platelets serve as assembly sites for the intrinsic tenase and prothrombinase complexes (21–25).

Procoagulant platelet subpopulations have been referred to by a myriad of names in the literature; however, it is recognized that these platelets share the key characteristic of PS exposure. An early description of a subpopulation of PS-exposing platelets was as COAT (Collagen And Thrombin)-FV platelets formed in response to dual agonist activation. These platelets were characterized by high levels of FV on their surface, in addition to PS (22, 26). COAT-FV was later abbreviated to COAT when it was demonstrated that these platelets are also coated with fibrinogen, fibronectin, von Willebrand factor (VWF), and thrombospondin, among many other α-granule proteins, on their surface (27). Subsequently, this subpopulation has been termed coated platelets, denoting the coating of the platelets with procoagulant proteins, including fibrin (28–30). The distinct morphology of procoagulant platelets has led to the terminology of bleeding, balloon(ing), or balloon-like platelets (31–35). Procoagulant platelets have also been referred to as SCIP (sustained calcium-induced platelet morphology) platelets (36), necrotic/4-[N-(S-glutathionylacetyl)aminol-phospholiparonous acid (GSAO)-binding platelets (37–39), superactivated platelets (40), capped platelets (21, 41), and zombie platelets (42). Aghani and Poole (43) recently proposed "procoagulant platelets" as the unifying term for this activated platelet subpopulation.

In this brief review, we focus on mechanisms involved in PS exposure induced by platelet activation to form a subpopulation of procoagulant platelets, then contrasting it with PS exposure resulting from platelet apoptosis. Pathologies of PS exposure, inherited and acquired, are described. We conclude with a consideration of platelet PS exposure as an antithrombotic target.

**PLATELET MEMBRANE PHOSPHATIDYL SERINE EXPOSURE**

Several different pathways result in procoagulant platelet formation. In one, PS exposure occurs rapidly via platelet activation by strong agonists. A second is the intrinsic apoptosis pathway via which PS exposure occurs more slowly (9, 37, 52, 53). These pathways are considered in turn below, and key characteristics are summarized in **Table 1**. In a recently described third pathway that is distinct from the aforementioned canonical pathways, binding of oxidized low-density lipoprotein to platelet membrane glycoprotein (GP)IV (CD36) and signaling through extracellular signal-regulated protein kinase (ERK)5 mitogen-activated protein (MAP) kinase leads to PS exposure. This pathway may be relevant in thrombotic events that occur in dyslipidemia (54).

**PLATELET MEMBRANE PHOSPHATIDYL SERINE ASYMMETRY: MAINTENANCE AND COLLAPSE**

**Flippase ([Aminophospholipid] Translocase)**

Similar to other biological membranes, resting platelets possess an asymmetrical phospholipid plasma membrane bilayer (4), with the minor phospholipid PS sequestered to the inner cytoplasmic leaflet. This PS asymmetry is created by a flippase/(amino)phospholipid translocase enzyme, a member of the Type IV subfamily of P-type ATPases (P4-ATPases) (9, 44), that rapidly and specifically shuttles PS from the outer to the inner membrane leaflet against the concentration gradient, in an ATP-dependent fashion (45). Its activity is abrogated when cytoplasmic Ca²⁺ (Ca²⁺_cyt) increases to low micromolar levels (46).

**Scramblase and TMEM16F**

Scramblase is a Ca²⁺-dependent, ATP-independent enzyme that regulates the rapid, non-specific bidirectional movement, i.e., “scrambling,” of phospholipids between membrane leaflets, resulting in a loss of normal membrane phospholipid bilayer asymmetry. Although scramblase activity has long been described in platelets (4), the protein involved in Ca²⁺-dependent PS exposure was only identified a decade ago as TMEM16F (anoctamin 6) (47–49). It is a member of the multiple transmembrane (TMEM)16 (anoctamin) domain family of proteins, of which the first-described member, TMEM16A, is a Ca²⁺-activated Cl⁻ channel. TMEM16F has been described to be a Ca²⁺-dependent Cl⁻ channel, a Ca²⁺-regulated non-selective cation channel permeable for Ca²⁺, or a Ca²⁺-dependent phospholipid scramblase (49). Evidence is accumulating that TMEM16F is indeed itself a scramblase [e.g., Watanabe et al. (50); Le et al. (51)].
TABLE 1 | Summary of key characteristics of platelet agonist- and apoptosis-induced PS exposure (Agnost-Induced Phosphatidylserine Exposure and Apoptosis-Induced Phosphatidylserine Exposure).

| Trigger | Physiologically relevant: engagement of both GPVI (collagen/convulin/CRP) and PAR1/PAR4 (thrombin) receptors | Non-physiological: Ca\(^{2+}\) ionophores A23187, ionomycin |
|---------|---------------------------------------------------|---------------------------------------------------|
| Cytoplasmic Ca\(^{2+}\) (Ca\(^{2+}\)\(_{cyt}\)) concentrations | Sustained, elevated Ca\(^{2+}\)\(_{cyt}\) levels required | Not dependent on sustained, elevated Ca\(^{2+}\)\(_{cyt}\) levels |
| Mitochondrial integrity | Loss of IMM integrity: • Dependence on MPTP formation • \(\Delta\Psi_m\) depolarization occurs | MOMP occurs early, with loss of IMM integrity occurring concomitant with PS exposure |
| Intracellular protease activation | Calpain activated | • Dependent on caspase activation |
| TMEM16F | Required | Not essential |
| Morphology | • Rounded, blebbing platelets essentially empty of cytoplasmic contents • EVs are shed | • Rounded, blebbing platelets with cytoplasmic contents remaining • EVs are shed |
| In vivo effects (in animal models) | In arterial thrombi, PS-exposing platelets form microdomains that do not participate in platelet aggregation • PS-exposing platelets continue to circulate in the bloodstream | • Formation of venous thrombi inhibited • Thrombocytopenia, with PS exposure persisting on remaining circulating platelets |

Ca\(^{2+}\)\(_{cyt}\), cytoplasmic Ca\(^{2+}\); CRP, collagen-related peptide; EV, extracellular vesicle; GP, glycoprotein; IMM, inner mitochondrial membrane; MOMP, mitochondrial outer membrane permeabilization; MPTP, mitochondrial permeability transition pore; PAR, protease-activated receptor; PS, phosphatidylserine; \(\Delta\Psi_m\), inner mitochondrial membrane potential.

Agonist-Induced Phosphatidylserine Exposure

Agonist-stimulated platelet surface PS exposure is a rapid process, occurring in seconds to minutes, and is accompanied by other apoptotic-like events, including mitochondrial membrane permeabilization and depolarization, and plasma membrane blebbing, with extracellular vesicle (EV) formation. The proportion of PS-exposing platelets formed depends on the agonist(s) used for platelet stimulation, with the most potent in vitro, physiologically relevant stimulus being the combination of collagen/convulin/collagen-related peptide (CRP) plus thrombin (C+T). The former binds to GPVI, and the latter cleaves protease-activated receptor (PAR)1 and PAR4 (23), synergizing to set into motion the signaling pathways that result in the sustained, supramaximal levels of Ca\(^{2+}\)\(_{cyt}\) (55) (see below) that are required for PS exposure on a substantial proportion of platelets. Anywhere from 20 to 40% of C+T-stimulated platelets become PS-exposing, with a wide variation between donors; singly, these agonists are not as potent, with a smaller proportion of PS-exposing platelets being formed (56). ADP or thromboxane A\(_2\) (TxA\(_2\)) (using the stable mimetic U46619) does not play a major role (23, 33), while shear forces are effective (57, 58). The non-physiological, non-receptor-mediated ionophores A23187, and ionomycin, that directly increase Ca\(^{2+}\)\(_{cyt}\), are the most potent stimulators of PS exposure, with typically >90% of platelets taking on the procoagulant phenotype (19, 56).

Platelet stimulation by collagen (or convulin/CRP) or thrombin [or the PAR-specific thrombin receptor activating peptides (TRAPs)] alone activates phospholipase (PL)Cy (via GPVI) and PLC\(\beta\) (via PAR1/4), resulting in a rise in Ca\(^{2+}\)\(_{cyt}\) to the micromolar range (23). Cleavage of membrane phosphatidylinositol-4,5-bisphosphate by PLC forms inositol trisphosphate (IP\(_3\)) and diacylglycerol (DAG); the former induces the release of Ca\(^{2+}\) from internal stores, the dense tubular system (DTS), via IP\(_3\) receptors. Depletion of internal Ca\(^{2+}\) stores allows store-operated Ca\(^{2+}\) entry (SOCE) from the platelet exterior: briefly, stromal interaction molecule 1 (STIM1) in the DTS membrane undergoes a conformational change, allowing activation of Orai1, the major Ca\(^{2+}\) release-activated Ca\(^{2+}\) channel in the platelet plasma membrane (23). DAG, together with Ca\(^{2+}\), activates protein kinase C (PKC)\(\alpha\) that enhances Na\(^+\)/Ca\(^{2+}\) exchange during SOCE (59, 60). Sustained increases in Ca\(^{2+}\)\(_{cyt}\) via release from internal stores, SOCE, and release of mitochondrial Ca\(^{2+}\) upon mitochondrial permeability transition pore (MPTP) formation (see below) in a small proportion of platelets activate scramblase. It is the dual stimulation of GPVI and PAR1/4 by C+T that leads to the sustained, elevated levels of Ca\(^{2+}\)\(_{cyt}\) necessary for PS exposure in a substantial proportion of platelets; the combination of C+T activates store-independent, receptor-operated Ca\(^{2+}\) entry (ROCE). This involves non-selective cation transient receptor potential C (TRPC) channels, TRPC3 and TRPC6, that allow Na\(^+\) entry. Coupling to reverse-mode Na\(^+\)/Ca\(^{2+}\) exchange then leads to the sustained elevated Ca\(^{2+}\)\(_{cyt}\) that activates scramblase (61).

Ca\(^{2+}\)\(_{cyt}\) increases activation of the Ca\(^{2+}\)-dependent cysteine protease calpain that has a number of substrates in platelets, including cytoskeletal components, signaling molecules, and
the β3 integrin subunit, thereby regulating many platelet responses, including spreading, secretion, aggregation, and EV formation (36, 62–64). In platelets stimulated to expose PS, calpain-2-mediated proteolysis of αIIbβ3-associated proteins and β3 results in inactivation of αIIbβ3, the integrin necessary for platelet aggregation (65); thus, procoagulant platelets are unable to participate in aggregation. To that end, both in flow chambers coated with collagen and in mouse models of arterial thrombosis, two distinct microdomains of platelets are visualized in thrombi: 1) aggregated, non-PS-exposing platelets with extended pseudopods and activated αIIbβ3; surrounded by 2) PS-exposing platelets that have elevated Ca$^{2+}$, inactivated αIIbβ3, a rounded morphology, and are shedding Ca$^{2+}$-cyt, intact αIIbβ3, and activated αIIbβ3. Further, in these ex vivo and in vivo systems, PS-exposing platelets are observed to translocate to the surface of thrombi where they accelerate fibrin formation (66).

Mitochondrial integrity loss is an apoptosis hallmark that precedes agonist-induced PS exposure, with involvement of the inner mitochondrial membrane (IMM) Formation of the cyclophilin D-regulated MPTP, a non-selective multiprotein pore that spans the IMM, is a key step (67, 68), as PS exposure is reduced in convulxin+thrombin-stimulated cyclophilin D-deficient platelets or platelets treated with cyclosporin A, an MPTP inhibitor (69–71). Reactive oxygen species, e.g., hydrogen peroxide (H$_2$O$_2$), that can trigger MPTPP formation, synergize with thrombin to expose platelet PS, indicating a role for oxidative stress in procoagulant platelet formation (69). Sustained MPTP formation leads to disruption of the IMM potential (∆Ψ$_m$) (72, 73), and ∆Ψ$_m$ depolarization is associated with PS exposure both in agonist-stimulated platelets in vitro and platelets aging in vivo (69, 71, 74–77).

In convulxin+thrombin-stimulated platelets, PS exposure is entirely dependent on ∆Ψ$_m$ loss and TMEM16F. However, there is evidence of a second minor pathway of PS exposure that occurs with collagen+thrombin stimulation that is independent of these (76, 78). This pathway may also be involved in the mitochondrial depolarization-independent PS exposure observed in A23187-stimulated platelets in the presence of cyclosporin A (79). Heterogeneity within the PS-exposing platelet subpopulation has also been reported by Topalov et al. (80): one subset with high Ca$^{2+}$-cyt, ∆Ψ$_m$ loss, and inactive αIIbβ3; and another with low Ca$^{2+}$-cyt, intact ∆Ψ$_m$, and active αIIbβ3. Subsequently, this latter subset was described to be the result of the interaction between a procoagulant platelet and an aggregatory (non-PS-exposing) platelet (81).

Although caspase activation occurs upon mitochondrial depolarization and has been used as a marker in studies of agonist-induced platelet PS exposure, e.g., caspase-3 (75, 79), the agonist-induced pathway of procoagulant platelet formation appears to be independent of caspase activation (52, 82).

Near-complete shedding of GPIbα and GPVI mediated by ADAM17 and 10, respectively, is accompanied by PS exposure and modulates platelet function from less adhesive to more procoagulant (83).

In becoming procoagulant, platelets undergo remarkable morphological changes. Platelets adherent to collagen/CRP, but not fibrinogen, spread and transform into blebbing, rounded, balloon-like structures (31, 34). These collagen-adherent balloon platelets are PS exposing, as determined by annexin A5 binding (32, 33). Similarly, platelets stimulated in suspension by Ca$^{2+}$ or A23187 form a distinct PS-exposing platelet subpopulation with a spherical, balloon-like morphology, almost devoid of granules and normal internal architecture (Figure 1) (35, 84). This ballooning has been attributed to activation of Ca$^{2+}$-activated Cl$^-$ channels, resulting in initial salt entry into platelets, which is then followed by the influx of water (33). There is increased permeability of plasma membrane of the PS-exposing platelets to low-molecular-weight molecules (33, 71).

The unique surface protein coating of procoagulant platelets (Introduction) has been observed primarily localized to a small, convex structure, or cap, rather than distributed uniformly on the PS-exposing platelet surface; 85% of PS-exposing platelets possess caps, with one per platelet (21, 41). It was subsequently demonstrated that procoagulant activity is located in the cap, or remnant platelet body, early in balloon-platelet development, then becomes predominant in the balloon-like structure at later time points (85). Recently, it was observed that more than 90% of PS-exposing platelets possess one or multiple associated EVs that exhibit heterogeneity in platelet membrane glycoproteins and activation markers different from platelet-derived EVs free in suspension (see below) (Figure 1) (35).

PS exposure is accompanied by the release of membrane-bound EVs (previously referred to as microparticles or microvesicles) from the platelet plasma membrane (86); indeed, Scott syndrome platelets, that are deficient in PS exposure upon activation (Pathologies of Phosphatidylserine Exposure), are also deficient in EV formation (87, 88). EV surface membranes are heterogeneous in their expression of platelet membrane glycoproteins, e.g., αIIbβ3 and GPIb-IX-V, and activation markers, e.g., CD62P (P-selectin), CD63, and activated αIIbβ3 (35, 89, 90), and only about half expose PS (86). Platelet-derived EVs support hemostasis and also play a role in platelet–cell communications, delivering bioactive molecules, e.g., cytokines, eicosanoids, RNA species, to target cells [e.g., Boilard et al. (91)]. Elevated circulating EV levels have been reported in thrombotic conditions, immune-mediated conditions, and malignancy and inflammatory conditions, but whether they are “active contributors” or “passive indicators” of these conditions is not known (86). EVs are cleared rapidly (92), implying that they must be produced continuously for circulating levels to be detected.

Once procoagulant platelet formation has been stimulated in vitro, PS exposure is not readily reversed; this is likely due, at least in part, to inhibition of translocase activity (56, 76, 93), preventing the flipping of PS to the internal membrane leaflet. Even in vivo, PS exposure persists on activated platelets, as demonstrated by a study in which rabbit platelets stimulated to expose PS in vitro continued to circulate when injected into recipient rabbits (94). Although PS is a clearance signal of apoptotic cells by macrophages (see below), there are examples of cells that express PS constitutively and are viable (95, 96).
FIGURE 1 | Upon platelet activation with collagen (10 µg/ml) + thrombin (1 U/ml) (C + T), a subpopulation of phosphatidylserine (PS)-exposing platelets with a round, balloon-like morphology and one or more associated extracellular vesicles (EVs) is formed. Resting (unstimulated) (A) or stimulated (B) washed platelets were labeled with anti-CD41-FITC (platelet marker) and annexin A5-Alexa Fluor 647 (PS exposure) and analyzed on an Amnis ImageStream® Mark II (ISX®) multispectral imaging flow cytometer. Images representative of n = 4 independent experiments.

It is still not clear why there is platelet response heterogeneity to becoming PS exposing. Certainly, it is not due to differences in overall platelet reactivity, as PS-exposing platelets express CD62P to the same extent as non-PS-exposing platelets (9), indicating that they are capable of the secretion event. Although it had previously been attributed to platelet age, with young platelets, identified by increased thiazole orange staining, having an enhanced capacity to take on a procoagulant phenotype (22, 97), uptake of this dye is increased in large platelets that are not necessarily young platelets in the steady state (98). Recently, it has been shown that young, newly produced, steady-state (rabbit) platelets are indeed less responsive in exposing PS than older platelets (98). It is speculated that differences in receptor expression levels and in Ca\textsuperscript{2+}-flux machinery activity are involved (99), and levels of adhesive receptors, including GPVI, GPIbα, αIIb, and β3, have been reported to be increased on procoagulant platelets (97, 100).

**Apoptosis-Induced Phosphatidylserine Exposure**

It is now well-recognized that platelets, although they are anucleate, can undergo apoptosis. This occurs via the intrinsic, mitochondrial-dependent pathway, with platelets possessing the necessary cytosolic machinery, while likely lacking the death receptors required for the extrinsic pathway (37, 101, 102). Platelet apoptosis can be initiated in vitro by ABT-737, a BH3-only protein mimetic, that inhibits the pro-survival Bcl-2 family protein Bcl-xL, resulting in activation of the proapoptotic Bcl-2 proteins Bak and Bax; these then go on to initiate mitochondrial damage, cytochrome c release, caspase activation, PS exposure, and membrane blebbing and EV formation (37, 52, 101), all hallmarks of apoptosis in nucleated cells.

In contrast to platelet agonist-induced PS exposure, which occurs rapidly, apoptosis-induced PS exposure occurs more slowly, on the order of hours (9, 37, 52, 53). This apoptosis
pathway is indeed Bak and Bax dependent, as platelets lacking these proteins do not externalize PS when incubated with ABT-737. It is also caspase dependent, as responses are abolished in the presence of a caspase inhibitor (52, 78). However, it does not require increases in Ca$^{2+}$_{cyt} or calpain activity, which are necessary for agonist-induced PS exposure (52) (A agonist-Induced Phosphatidylerine Exposure). There is early mitochondrial outer membrane permeabilization (MOMP), followed by later IMM disruption concomitant with PS exposure (81): MPTP formation may not be involved, and ΔΨ_{m} depolarization may occur (52, 103–105). PS-exposing platelets take on a rounded morphology but maintain cytoplasmic components (105, 106); EV formation is not observed early on, but increases with time (103, 104, 107).

ABT-737 treatment of platelets has also been reported to result in PS exposure on a second platelet population at a higher level, observed with agonist-induced PS exposure, than described above. PS exposure on this population is dependent on increases in Ca$^{2+}$_{cyt} and TMEM16F but unlike agonist-induced PS exposure is dependent on caspase activation (78, 107).

Apoptosis, being the process of programmed cell death, is a major physiological mechanism that regulates the life span of cells, with externalized PS being the “eat me” recognition signal for phagocytic cells to mediate clearance of damaged cells (108). Platelet apoptosis regulates circulating platelet life span, as mutations in Bcl-xL result in shortened platelet survival, while deletion of Bak and Bax prolongs it by almost 2-fold (109, 110). Administration of ABT-737 to dogs and mice causes dramatic thrombocytopenia within 2 h (109, 111), but PS exposure persists on the circulating platelets (106); formation of venous thrombi is inhibited (106). Platelet PS exposure may be involved in physiological platelet clearance; the proportion of PS-exposing platelets increases as rabbit platelets age in the circulation under steady-state conditions (77).

**PATHOLOGIES OF PHOSPHATIDYLERINE EXPOSURE**

The importance of activated platelet membrane phospholipid bilayer scrambling with resulting PS exposure in hemostasis is highlighted in the very rare inherited autosomal recessive disorder Scott syndrome. The first-described patient, Mrs. M.A. Scott, had a relatively severe bleeding phenotype: she was found to have an isolated defect in PF3a (Introduction) (112); impaired PS exposure upon platelet activation, thereby resulting in deficient procoagulant activity and abrogated fibrin formation at sites of vascular damage (3, 113); and diminished EV formation (A agonist-Induced Phosphatidylerine Exposure). The genetic defect in four of the six known Scott syndrome patients for whom mutational analysis is available, as well as in canine Scott syndrome, in German Shepherd dogs, involves homozygous and heterozygous variants in the TMEM16F gene (47, 49, 114–118), resulting in an absence of expression of the TMEM16F protein (Scramblase and TMEM16F) Knockout of TMEM16F in genetically modified mice recapitulates the Scott syndrome phenotype (119–122).

Studies of Scott syndrome platelets have shown that, in humans, TMEM16F is required for the major agonist-induced PS exposure pathway but is not essential for apoptosis-induced PS exposure (78). In contrast, in dogs, both agonist- and apoptosis-induced platelet PS exposure requires TMEM16F (116). Detailed proteomic profiling of human Scott syndrome platelets has provided insight into protein modifications that occur when platelets are activated to expose PS (123).

In contrast with the Scott syndrome, in the rare autosomal dominant Stromorken syndrome, resting platelets have elevated surface PS exposure; resting Ca$^{2+}$_{cyt} is increased due to a novel STIM1 gain-of-function variant. Stromorken syndrome patients have thrombocytopenia and a mild bleeding diathesis along with their thrombocytopenia (124).

Another inherited disorder in which elevated PS exposure and Ca$^{2+}$_{cyt} is observed with resting platelets is the microthrombocytopenia, Wiskott–Aldrich syndrome (WAS). Upon stimulation, WAS platelets have increased susceptibility to PS exposure that occurs as a result of MPTP opening (125, 126).

Resting platelets from Bernard–Soulier syndrome patients also have elevated PS exposure, independent of their large size (127), indicating a role for GPIb-IX-V. PS exposure is generally increased in activated BSS platelets as well and is accompanied by ΔΨ_{m} depolarization in a proportion of platelets (127).

Aberrant PS exposure has been described in certain acquired platelet disorders. Platelets from patients with immune thrombocytopenia have increased (apoptosis-induced) PS exposure likely contributing to the decreased platelet counts (128, 129). Recently, there has been the report of increased circulating PS-exposing ballooned platelets in trauma hemorrhage in response to the damage-associated molecular pattern histone H4, demonstrating a mechanism by which platelets respond to tissue damage (130).

**CONCLUSION: POTENTIAL OF PROCOAGULANT PHOSPHATIDYLERINE-EXPOSING PLATELETS AS AN ANTITHROMBOTIC TARGET**

Understanding of the mechanisms involved in the formation of the procoagulant PS-exposing platelet phenotype and its role in hemostasis has increased dramatically. Since traditional antiplatelet agents do not completely reduce the risk of thromboembolic events, the question arises: Is PS exposure a useful antithrombotic target? Not surprisingly, drugs that target the ADP and TxA2 pathways of platelet activation and aggregation have no major effect on inhibiting platelet procoagulant activity (38, 131, 132) since these agonists are not particularly potent in stimulating the formation of PS-exposing platelets (A agonist-Induced Phosphatidylerine Exposure). There are certainly indications that the procoagulant platelet might be a useful target in reducing thrombosis.

Firstly, knockout of TMEM16F in platelets of genetically...
modified mice (Pathologies of Phosphatidylserine Exposure) decreases platelet thrombus formation in vitro on collagen-coated coverslips under flow conditions and in models of arterial and venous thrombosis (119–122). Secondly, there is evidence that in clinical conditions of thrombosis, specifically coronary artery disease, and essential thrombocytopenia, the procoagulant platelet response is increased, and that increased levels of procoagulant platelets are associated with increased risk for recurrent infarction in lacunar and non-lacunar stroke and predict incident stroke after transient ischemic attack (131, 133–136). Thirdly, procoagulant platelets have recently been shown to play a critical role in forming neutrophil macroaggregates that promote pulmonary thrombosis after gut ischemia that is a potent inducer of platelet PS exposure on the endothelium in the intestines, liver, and lungs; large membrane fragments ripped from PS-exposing platelets in a shear-dependent fashion wrap around the neutrophils to form adhesive bridges (137).

Thus, since PS exposure persists on activated platelets not only in vitro but in vivo as well (76, 94), blocking of the procoagulant surface could be an effective, novel strategy to reduce thrombosis. By binding to PS, annexin A5, diannexin [a recombinant annexin A5 homodimer with a longer circulating half-life than annexin A5 and a 10-fold higher binding affinity to PS (138, 139)] and lactadherin inhibit thrombus formation in vitro and in animal models of arterial and venous thrombosis (139–145). However, diannexin and lactadherin impair hemostasis as well, increasing murine tail bleeding time blood loss (139, 145); thus, if a strategy of blocking exposed PS is to be pursued, dosages of blocking compounds must be finely tuned.

Alternatively, mitochondrial depolarization (70), scramblase activity (146, 147), or water entry into platelets (33, 148) are potential targets to inhibit formation of the thrombin-generating subpopulation of platelets while still allowing platelet aggregation to occur. It may be that inhibition of procoagulant platelet formation could be an alternative approach to reduce thrombosis without impairing hemostasis.

**AUTHOR CONTRIBUTIONS**

All authors listed have made a substantial, direct and intellectual contribution to the work, and approved it for publication.
concentrate in cap structures to promote clotting. Blood. (2016) 128:1745–55. doi: 10.1182/blood-2016-02-696989
22. Alberio A, Safa O, Clemetson KJ, Esmon CT, Dale GL. Surface expression and functional characterization of alpha-granule factor V in human platelets: effects of ionophore A23187, thrombin, collagen, and convulxin. Blood. (2000) 96:7694–703. doi: 10.1182/blood.V96.22.7694.2000
23. Heemskerk JW, Mattheij NJ, Cosemans JM. Platelet-based coagulation: different populations, different functions. J Thromb Haemost. (2013) 11:2–16. doi: 10.1111/jth.12045
24. Swieringa F, Sprock HHM, Heemskerk JWM, van der Meijden JPE. Integrating platelet and coagulation activation in fibrin clot formation. Res Pract Thromb Haemost. (2018) 2:450–460. doi: 10.1002/rth2.12107
25. London FS, Marcinkiewicz M, Walsh PN. A subpopulation of platelets responds to thrombin- or SFLLRN-stimulation with binding sites for factor IXa. J Biol Chem. (2004) 279:19854–9. doi: 10.1074/jbc.M310624200
26. Alberio LJ, Clemetson KJ. All platelets are not equal: COAT platelets. Curr Hematol Rep. (2004) 3:338–43
27. Dale GL, Friese P, Batar P, Hamilton SF, Reed GL, Jackson KW, et al. Stimulated platelets use serotonin to enhance their retention of procoagulant proteins on the cell surface. Nature. (2002) 415:175–9. doi: 10.1038/415175a
28. Dale GL. Coated-platelets: an emerging component of the procoagulant response. J Thromb Haemost. (2005) 3:2185–92. doi: 10.1111/j.1538-7836.2005.01274.x
29. Mattheij NJ, Swieringa F, Mastenbroek TG, Berry-Lang MA, May F, Baaten CC, et al. Coated platelets function in platelet-dependent fibrin formation via integrin αIIbβ3 and transglutaminase factor XIII. Haematologica. (2016) 101:427–36. doi: 10.3342/haematol.2015.131441
30. van der Meijden JPE, Heemskerk MJW. Platelet biology and functions: new concepts and clinical perspectives. Nat Rev Cardiol. (2019) 16:166–179. doi: 10.1038/s41569-018-0110-0
31. Heemskerk JW, Vuist WM, Feijge MA, Reutelingsperger CP, Lindhout T. Collagen but not fibrinogen surfaces induce bleb formation, exposure of phosphatidylserine, and procoagulant activity of adherent platelets: evidence for regulation by protein tyrosine kinase-dependent Ca2+ responses. Blood. (1997) 90:2615–23. doi: 10.1182/blood.V90.7.2615.2615_2625
32. Munnix IC, Kuijpers MJ, Auger I, Thomassen CM, Panizzi P, van MA, et al. Segregation of platelet aggregate and procoagulant microdomains in thrombus formation: regulation by transient integrin activation. Arterioscler Thromb Vasc Biol. (2007) 27:2484–90. doi: 10.1161/ATVBAHA.107.151100
33. Ağbani EO, den Bosch VMT, Brown E, Williams CM, Mattheij NJ, Cosemans JM, et al. Coordinated membrane ballooning and procoagulant spreading in human platelets. Circulation. (2015) 132:1414–24. doi: 10.1161/CIRCULATIONAHA.114.015036
34. Hess MW, Siljander P. Procoagulant platelet balloons: evidence from cryo-preparation and electron microscopy. Histochem Cell Biol. (2001) 115:439–43. doi: 10.1007/s000180100272
35. Reddy EC, Wang H, Christensen H, McMillan-Ward E, Israels SJ, Bang KWA, et al. Analysis of procoagulant phosphatidylserine-exposing platelets by imaging flow cytometry. Res Pract Thromb Haemost. (2018) 2:736–750. doi: 10.1002/rth2.12144
36. Kulkarni S, Jackson SP. Platelet factor XII and calpain negatively regulate integrin αIIbβ3 adhesive function and thrombus growth. J Biol Chem. (2004) 279:30697–706. doi: 10.1074/jbc.M405592000
37. Jackson SP, Schoenwaelder SM. Procoagulant platelets: are they necrotic? Blood. (2011) 116:2011–8. doi: 10.1182/blood-2010-01-266169
38. Hua VM, Chen VM. Procoagulant platelets and the pathways leading to cell death. Semin Thromb Hemost. (2015) 41:405–12. doi: 10.1055/s-0035-1544002
39. Mazega M, Hoffman M, Monroe D. Superactivated platelets: thrombus regulators, thrombin generators, and potential clinical targets. Arterioscler Thromb Vasc Biol. (2013) 33:1747–52. doi: 10.1161/ATVBAHA.113.301790
40. Alberio L, Ravanat C, Hechler B, Mangin PH, Lanza F, Gachet C. Delayed-onset of procoagulant signalling revealed by kinetic analysis of COAT platelet formation. Thromb Haemost. (2017) 117:1101–14. doi: 10.1161/TH16-09-0711
41. Harper MT, Londoño JE, Quick K, Londoño JC, Flockeiri V, Philipp SE, et al. Transient receptor potential channels function as a coincidence signal
detector mediating phosphatidylserine exposure. Sci Signal. (2013) 6:ra50. doi: 10.1126/scisignal.2003701

62. Croce K, Flammenga R, Rivers M, Furie B, Furie BC, Herman IM, et al. Inhibition of calpain blocks platelet secretion, aggregation, and spreading. J Biol Chem. (1999) 274:36321–7. doi: 10.1074/jbc.274.51.36321

63. Schonwezelder SM, Yuan Y, Jackson SP. Calpain regulation of integrin αIIbβ3 signaling in human platelets. Platelets. (2000) 11:189–98. doi: 10.1080/0953705005007620

64. Fox JE. Cytoskeletal proteins and platelet signaling. Thromb Haemost. (2001) 86:198–213. doi: 10.1055/s-0037-1612168

65. Matthei NJ, Gilió K, van Kruchten R, Jobe SM, Wieschhaus AJ, Chishti AH, et al. Dual mechanism of integrin αIIbβ3 closure in procoagulant platelets. J Biol Chem. (2013) 288:13325–36. doi: 10.1074/jbc.M112.428339

66. Nechipurenko DY, Receveur N, Yakimenko AO, Shepelyuk TO, Yaksheva KA, Kerimov NR, et al. Clot contraction drives the translocation of procoagulant platelets to thrombus surface. Arterioscler Thromb Vasc Biol. (2019) 39:37–47. doi: 10.1161/ATVBAHA.118.311390

67. Baines CP, Kaiser RA, Purcell NH, Blair NS, Osinska H, Hambleton MA, et al. Two types of procoagulant platelets are formed upon B cell receptor activation. J Immunol. (2009) 183:2512–20. doi: 10.4049/jimmunol.183.4.2512

68. Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernardi P. Properties of the permeability transition pore in coated-platelet formation. Mol Cell Biochem. (1994) 134:151–7. doi: 10.1007/BF00689702

69. Jobe SM, Wilson KM, Leo L, Raimondi A, Molkentin JD, Lentz SR, et al. Critical role for the mitochondrial permeability transition pore and Cyclophilin D in platelet activation and thrombosis. Blood. (2008) 111:1257–65. doi: 10.1182/blood-2007-05-092684

70. Choo HJ, Saafr TB, Mkumba L, Wagner MB, Jobe SM. Mitochondrial calcium and reactive oxygen species regulate agonist-initiated platelet phosphatidylserine exposure. Arterioscler Thromb Vasc Biol. (2012) 32:2946–55. doi: 10.1161/ATVBAHA.112.300435

71. Remenyi G, Szast R, Friese P, Dale GL. Role of mitochondrial transition pore in mitochondria devoid of Cyclophilin D. J Biol Chem. (2005) 280:18558–61. doi: 10.1074/jbc.C500089200

72. Petit PX, Zamani N, Vayssière JL, Mignotte B, Kroemer G, Castedo M. Implication of mitochondria in apoptosis. Mol Cell Biochem. (1997) 174:185–8. doi: 10.1007/978-1-4615-6111-8_28

73. Halsetrap AR, McStay GP, Clarke SJ. The permeability transition pore complex: another view. Biochimica. (2002) 84:153-66. doi: 10.1016/S0006-3008(02)01375-5

74. Leytin V, Freedman J. Platelet apoptosis in stored platelets: involvement of apoptosis and aminophospholipid translocase. J Thromb Haemost. (2007) 5:560–70. doi: 10.1111/j.1538-7836.2007.02393.x

75. Rand ML, Wang H, Bang KW, Packham MA, Freedman J. Procoagulant surface exposure and apoptosis in rabbit platelets: association with shortened survival and steady-state senescence. J Thromb Haemost. (2004) 2:651–9. doi: 10.1111/j.1538-7836.2004.00670.x

76. van Kruchten R, Mattheij NJ, Saunders C, Feijge MA, Swierenga F, Boilard E, Duchez AC, Brisson A. The diversity of platelet procoagulant activity. Curr Opin Hematol. (2015) 22:437–44. doi: 10.1097/MOH.0000000000000166

77. Agbani EO, Scott syndrome: a disorder of platelet coagulant activity. Semin Hematol. (1994) 31:312–9.

78. Gusecka A, Nieuwland R, Siljander PR-M. Platelet-derived extracellular vesicles. In: A. Michelson, M. Cattaneo, A. Frelinger and P. Newman editors. Platelets 4th ed. London: Academic Press Platelets (2019). p. 401–16. doi: 10.1016/B978-0-12-813456-6.00022-9

79. Leytin V, Freedman J. Surface exposure of phosphatidylserine on activated platelets: role of the permeability transition pore and Cyclophilin D. (2005) Arterioscler Thromb Vasc Biol. 25:467–71. doi: 10.1161/01.ATV.0000152726.49229.bf

80. Leytin V, Allen DJ, Mykhaylov S, Lyubimov E, Freedman J. Binding a functional prothrombinase. Blood. (1999) 94:1683–92. doi: 10.1182/blood.V94.5.1683

81. Reddy EC, Wang H, Bang AKW, Packham MA, Rand ML. Young procoagulant platelets: Procoagulant Platelets in vitro et in vivo. doi: 10.1111/ATVBAHA.112.235765

82. Choo HJ, Kholmukhamedov A, Zhou C, Jobe S. Nature03434

83. Wolf BB, Goldstein JC, Stennicke HR, Beere H, Amarante-Mendes GP, Salvesen GS, et al. Platelet functions in a caspase-independent manner to promote apoptosis-like events during platelet activation. Blood. (1999) 94:1683–92. doi: 10.1182/blood.V94.5.1683

84. Baeten FCCM, Swierenga F, Misztal T, Mastenbroek TG, Feijge HMA, Bock PE, et al. Platelet heterogeneity in activation-induced glycoprotein shedding: functional effects. Blood Adv. (2018) 2:2320–31. doi: 10.1182/bloodadvances.2017101544

85. Boilard E, White JG, Rao GH. Effects of the ionophore A23187 on the blood platelets II. Influence on ultrastructure. Am J Pathol. (1974) 77:151–66.

86. Reed KL. Persistence of procoagulant platelet-derived microparticles from the circulation of rabbits. J Thromb Haemost. (1999) 274:36321–7. doi: 10.1074/jbc.274.51.36321

87. Rabinovich SG, Suzuki J, Nagata S. Constitutive exposure of phosphatidylserine on activated platelets: implications for in vivo and in vitro studies. J Thromb Haemost. (2007) 5:560–70. doi: 10.1111/j.1538-7836.2007.02393.x

88. Boilard E, McStay GP, Clarke SJ. The permeability transition pore complex: another view. Biochimica. (2002) 84:153-66. doi: 10.1016/S0006-3008(02)01375-5

89. Leytin V, Freedman J. Platelet apoptosis in stored platelets: association with shortened survival and steady-state senescence. J Thromb Haemost. (2004) 2:651–9. doi: 10.1111/j.1538-7836.2004.00670.x

90. van Kruchten R, Mattheij NJ, Saunders C, Feijge MA, Swierenga F, Wolfs JL, et al. Both TMEM16F-dependent and TMEM16F-independent pathways contribute to phosphatidylserine exposure in platelet apoptosis and platelet activation. Blood. (2013) 121:1850–7. doi: 10.1182/blood-2012-09-45314

91. Leytin V, Allen DJ, Mutia A, Gryulkandzanyan AV, Mykhaylov S, Freedman J. Mitochondrial control of platelet apoptosis: effect of cyclosporin A, an inhibitor of the mitochondrial permeability transition pore. Lab Invest. (2009) 89:374–84. doi: 10.1038/labinvest.2009.13

92. Topalov NN, Yakimenko AO, Canault M, Artemenko EO, Zakharova NV, Abaeva AA, et al. The two types of procoagulant platelets are formed upon physiologic activation and are controlled by integrin αGIβ2. Arterioscler Thromb Vasc Biol. (2012) 32:2475–83. doi: 10.1161/ATVBAHA.112.235765

93. Choo HJ, Kholmukhamedov A, Zhou C, Jobe S. Nature03434
99. Baeten CCMJ, Ten Cate H, van der Meijden JPE, Heemskerk JWM. Platelet populations and priming in hematological diseases. Blood Rev. (2017) 31:389–99. doi: 10.1016/j.brrev.2017.07.004
100. Furukawa H, Clemenson KJ, Deguchi H, Kunicki TJ. Variation in human platelet glycoprotein VI content modulates glycoprotein VI-specific prothrombinase activity. Arterioscler Thromb Vasc Biol. (2001) 21:1857–63. doi: 10.1161/hjpt.1996.643
101. Leytin V. Apoptosis in the anucleate platelet. Blood. (2012) 126:51–63. doi: 10.1016/j.br2011.10.002
102. Winkel J, Rand ML, Schmugge M, Speer O. Omi/HtrA2 and XIAP are components of platelet apoptosis signalling. Thromb Haemost. (2013) 109:532–9. doi: 10.1160/TH12-06-0404
103. Gyulkhandanyan AV, Mutlu A, Allen DJ, Freedman J, Leytin V. BH3-mimetic ABT-737 induces strong mitochondrial membrane depolarization in platelets but only weakly stimulates apoptotic morphological changes, platelet shrinkage and microparticle formation. Thromb Res. (2014) 133:73–9. doi: 10.1016/j.thromres.2013.10.041
104. Gyulkhandanyan AV, Mutlu A, Freedman J, Leytin V. Mitochondrial permeability transition pore (MPTP)-dependent and -independent pathways of mitochondrial membrane depolarization, cell shrinkage and microparticle formation during platelet apoptosis. Br J Haematol. (2015) 169:142–5. doi: 10.1111/bjh.13180
105. Vogler M, Hamali HA, Sun XM, Bampton ET, Dinsdale D, Snowden RT, et al. BCL2/BCL-XL inhibition induces apoptosis, disrupts cellular calcium homeostasis, and prevents platelet activation. Blood. (2011) 117:7145–54. doi: 10.1182/blood-2011-03-344812
106. Schoenwaelder SM, Jarman KE, Gardiner EE, Hua M, Qiao J, White MJ, et al. A new mutation of ANO6 in two familial cases of Scott syndrome. Br J Haematol. (2012) 163:812–20. doi: 10.1111/j.1365-2141.2011.08483.x
107. Mattheij NJ, Braun A, van Kruchten R, Castoldi E, Pircher J, Baeten CC, et al. Survival protein anoctamin-6 controls multiple platelet responses including phospholipid scrambling, swelling, and protein cleavage. FASEB J. (2016) 30:727–37. doi: 10.1096/fj.15-280446
108. Baig AA, Haining EL, Geus E, Beck S, Swierenga F, Wanitchakool P, et al. Nieswandt: TMEM16F-mediated platelet membrane phospholipid scrambling is critical for hemostasis and thrombosis but not thromboinflammation in mice. Proc Natl Acad Sci USA. (2015) 112:12800–5. doi: 10.1073/pnas.1516594112
109. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, et al. Nieswandt: TMEM16F-mediated platelet membrane phospholipid scrambling is critical for hemostasis and thrombosis but not thromboinflammation in mice. Proc Natl Acad Sci USA. (2015) 112:12800–5. doi: 10.1073/pnas.1516594112
110. Solari FA, Mattheij NJ, Burkhart JM, Swierenga F, Collins PW, Cosemans JM, et al. Combined quantification of the global proteome, phosphoproteome, and proteolytic cleavage to characterize altered platelet functions in the human scott syndrome. Mol Cell Proteomics. (2016) 15:3154–69. doi: 10.1002/mcp.M11606368
111. Misceo D, Holmgren A, Luch WE, Holme PA, Mizobuchi M, Morales RJ, et al. A dominant STIM1 mutation causes Stormorken syndrome. Hum Mutat. (2018) 39:536–64. doi: 10.1002/humu.23244
112. Shcherbina A, Rosen F, Remold-O'Donnell E. Pathological events in platelets of Wiskott-Aldrich syndrome patients. Br J Haematol. (1999) 106:875–83. doi: 10.1046/j.1365-2141.1999.01637.x
113. Obydennyi SI, Artemenko EO, Sveshnikova AN, Ignatova AA, Varlamova TV, Gambaryan S, et al. Mechanisms of increased mitochondria-dependent necrosis in Wiskott-Aldrich syndrome platelets. Haemostatohaematologica. (2019) 2018:214460. doi: 10.3324/haematol.2018.214460
114. Rand ML, Wang H, Bang KW, Tietel JM, Blanchette VS, Freedman J, et al. Phosphatidylserine exposure and other apoptotic-like events in Bernard-Soulier syndrome platelets. Am J Hematol. (2010) 85:584–92. doi: 10.1002/ajh.21768
115. Catani L, Fagioli ME, Tazzi PL, Ricci F, Curti A, Rovito M, et al. Dendritic cells of immune thrombocytopenic purpura (ITP) show increased capacity to present apoptotic platelets to T lymphocytes. Exp Hematol. (2006) 34:879–87. doi: 10.1016/j.exphem.2006.03.009
116. Winkel J, Kroijs S, Rand ML, Azzouzi I, Annie Bang KW, Speer O, et al. Platelet apoptosis in paediatric immune thrombocytopenia is ameliorated by intravenous immunoglobulin. Br J Haematol. (2012) 156:508–15. doi: 10.1111/j.1365-2141.2011.08973.x
117. Vulliamy P, Gillespie S, Armstrong PC, Allan HE, Warner TD, Brohi K. Histone H4 induces platelet ballooning and microparticle release during trauma hemorrhage. Proc Natl Acad Sci USA. (2019) 116:17444–4. doi: 10.1073/pnas.1904978116
118. Pasalic L, Wing-Lun E, Lau JK, Campbell H, Penningns GJ, Lau E, et al. Novel assay demonstrates that coronary artery disease patients have heightened procoagulant platelet response. J Thromb Haemost. (2016) 14:1198–210. doi: 10.1111/jth.14008
119. Agbani EO, Williams CM, Hers I, Poole AW. Membrane ballooning and thrombosis. Cereb Blood Flow Metab. (2013) 33:278–92. doi: 10.1038/cbfm.2012.168
120. Kirkpatrick AC, Tafur AJ, Vincent AS, Dale GL, Prodan CI. Coated-platelet levels are higher in coronary artery disease patients than in controls. J Thromb Haemost. (2015) 13:3154–69. doi: 10.1111/jth.13157
121. Brooks MB, Catalfamo JL, MacNagay R, Tim D, Fancher S, Cardille JA. A TMEM16F point mutation causes an absence of canine platelet TMEM16F and ineffective activation and death-induced phospholipid scrambling. J Thromb Haemost. (2015) 13:2240–52. doi: 10.1111/jth.13157
122. Flores-Nascimiento MC, Orsi FL, Yokoyama AP, Pereira FG, Lorand-Metze I, De EV, et al. Diagnosis of Scott syndrome in patient with bleeding disorder of unknown cause. Blood Coagul Fibrinolysis. (2012) 23:75–7. doi: 10.1097/MBC.0b013e3283cddc81
123. Millington-Burgess SL, Harper MT. Gene of the issue. Platelets. (2019) 1–4. doi: 10.1080/09537041.2019.1693039
Reddy and Rand Procoagulant Platelets

136. Kirkpatrick AC, Vincent AS, Dale GL, Prodan CI. Increased platelet procoagulant potential predicts recurrent stroke and TIA after lacunar infarction. *J Thromb Haemost.* (2019). doi: 10.1111/jth.14714. [Epub ahead of print].

137. Yuan Y, Alvìs Í, Wu LMC, Kaplan Z, Ashworth K, Bark D, et al. Neutrophil macroaggregates promote widespread pulmonary thrombosis after gut ischemia. *Sci Transl Med.* (2017) 9:aam5861. doi: 10.1126/scitranslmed.aam5861

138. Kuypers FA, Larkin SK, Emeis JJ, Allison AC. Interaction of an annexin V homodimer (Diannexin) with phosphatidylserine on cell surfaces and consequent antithrombotic activity. *Thromb Haemost.* (2007) 97:478–86. doi: 10.1160/TH06-08-0436

139. Rand ML, Wang H, Pluthero FG, Stafford AR, Ni R, Vaezzadeh N, et al. Diannexin, an annexin A5 homodimer, binds phosphatidylserine with high affinity and is a potent inhibitor of platelet-mediated events during thrombus formation. *J Thromb Haemost.* (2012) 10:1109–19. doi: 10.1111/j.1538-7836.2012.04716.x

140. Galán AM, van Heerde WL, Escolar G, Ordinas A, Sixma J, de Groot PG. Antithrombotic action of annexin V proved as efficient as direct inhibition of tissue factor or thrombin. *Eur J Clin Invest.* (2006) 36:633–9. doi: 10.1111/j.1365-2362.2006.01698.x

141. Römisch J, Seiffge D, Reiner G, Pàques EP, Heimburger N. In-vivo antithrombotic potency of placenta protein 4 (annexin V) *Thromb Res.* (1991) 61:93–104. doi: 10.1016/0049-3848(91)90236-P

142. Van Ryn-McKenna J, Merk H, Müller HT, Buchanan MR, Eisert WG. The effects of heparin and annexin V on fibrin accretion after injury in the jugular veins of rabbits. *Thromb Haemost.* (1993) 69:227–30. doi: 10.1055/s-0038-1651585

143. Thiagarajan P, Benedict CR. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. *Circulation.* (1997) 96:2339–47. doi: 10.1161/01.CIR.96.7.2339

144. Kuijpers MJ, Munnix IC, Cosemans JM, Vlijmen BV, Reutelingsperger CP, Egbrink MO, et al. Key role of platelet procoagulant activity in tissue factor- and collagen-dependent thrombus formation in arterioles and venules in vivo differential sensitivity to thrombin inhibition. *Microcirculation.* (2008) 15:269–82. doi: 10.1080/1073968070163517

145. Shi J, Pipe SW, Rasmussen JT, Heegaard CW, Gilbert GE. Lactadherin blocks thrombosis and hemostasis in vivo: correlation with platelet phosphatidylserine exposure. *J Thromb Haemost.* (2008) 6:1167–74. doi: 10.1111/j.1538-7836.2008.03010.x

146. Millington-B Burgess SL, Rahman T, Harper MT. An empirical screen of the effects of polyphenolic compounds on platelet scramblase activity. *Res Pract Thromb Haemost.* (2019) 3(Suppl.1):571

147. Millington-B Burgess SL, Rahman T, Harper MT. R5421 is not a selective inhibitor of platelet phosphatidylserine exposure. *Res Pract Thromb Haemost.* (2019) 3(Suppl.1):148–9.

148. Aghani EO, Williams CM, Li Y, van den Bosch MT, Moore SF, Mauroux A, et al. Aquaporin-1 regulates platelet procoagulant membrane dynamics and in vivo thrombosis. *JCI Insight.* (2018) 3:99062. doi: 10.1172/jci.insight.99062

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Reddy and Rand. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.